Zanubrutinib May Have PFS Edge Over Combo Therapy in CLL

by admin | Apr 28, 2026 | Health

Spread the love

A post hoc analysis evaluates zanubrutinib vs acalabrutinib-venetoclax in treatment naive chronic lymphocytic leukemia using indirect comparisons of data from two phase 3 trials.
Medscape Medical News

← Zanubrutinib May Have PFS Edge Over Combo Therapy in CLL UK Clinical Trial Regulations Come Into Force →

Written By

Written by Albert Pham, News Curator and Blogger

Type 2 Diabetes Symptoms: 5 Early Warning Signs to Know

Oct 12, 2026 | albertpham, Health

Frequent thirst, fatigue, blurred vision and unexplained weight changes may signal type 2 diabetes. Learn the warning signs and when to seek medical advice.

Newfoundland and Labrador’s Changing Demographics Boost Demand for Local Lamb

Oct 12, 2026 | albertpham, Economy_finances, Health

Changing demographics in Newfoundland and Labrador are boosting demand for local lamb, creating opportunities for sheep farmers, grocers and regional food producers.

AI Startup Red Queen Bio Uses Artificial Intelligence to Prepare for a Future Pandemic

Sep 28, 2026 | albertpham, Economy_finances, Health, Technology

Red Queen Bio is using AI to design antibody drugs against novel pathogens, highlighting the growing role of artificial intelligence in pandemic preparedness and biotech.

Zanubrutinib May Have PFS Edge Over Combo Therapy in CLL

Written By

Related Posts

Type 2 Diabetes Symptoms: 5 Early Warning Signs to Know

Newfoundland and Labrador’s Changing Demographics Boost Demand for Local Lamb

AI Startup Red Queen Bio Uses Artificial Intelligence to Prepare for a Future Pandemic

0 Comments

Explore More

Connect With Us

Quick Links

Legal

Stay Updated